Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2013
Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00743119 (Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers), which is not on this map. Cited by 47 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers
Who cites it
47 citing papers in PubMed, 3 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Pooled it
- Association of Cannabinoid Administration With Experimental Pain in Healthy Adults: A Systematic Review and Meta-analysis.JAMA psychiatry · 2018Pooled it
- Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations.Canadian family physician Medecin de famille canadien · 2014Pooled it
- A preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder.Journal of psychiatric research · 2024Trial
- Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within-subject, randomized, placebo-controlled laboratory study.Addiction biology · 2023Trial
- Signaling-specific inhibition of the CBNature medicine · 2023Trial
- Distress tolerance and cannabis craving: The impact of laboratory-induced distress.Experimental and clinical psychopharmacology · 2019Trial
- Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018Trial
- Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the achieving cannabis cessation-evaluating N-acetylcysteine treatment (ACCENT) study.The American journal on addictions · 2017Trial
- Sex-dependent effects of cannabis-induced analgesia.Drug and alcohol dependence · 2016Trial
- Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Human behavioral pharmacology of cannabis: Insights on cannabis use disorder.Preventive medicine · 2026Article
- The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.Experimental and clinical psychopharmacology · 2026Article
- Memory impairment and chronic high-dose Δ9-THC/cannabis exposure: a narrative review of molecular mechanisms underlying neurotoxic effects.Psychopharmacology · 2026Review
- Delta-9-tetrahydrocannabinol and Cannabidiol for Pain: Preclinical and Clinical Models.Current topics in behavioral neurosciences · 2026Review
- The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacological reviews · 2024Review
- Knowledge and Attitudes of Cannabidiol in Croatia among Students, Physicians, and Pharmacists.Pharmacy (Basel, Switzerland) · 2023Article
- Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance Use.Cannabis and cannabinoid research · 2023Article
- Sex differences in the subjective and reinforcing effects of smoked cannabis.Addiction biology · 2023Article
- Effects of Δ⁹-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC/CBD mixtures on fentanyl versus food choice in rhesus monkeys.Drug and alcohol dependence · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Recent studies have demonstrated the therapeutic potential of cannabinoids to treat pain, yet none have compared the analgesic effectiveness of smoked marijuana to orally administered Δ(9)-tetrahydrocannabinol (THC; dronabinol). This randomized, placebo-controlled, double-dummy, double-blind study compared the magnitude and duration of analgesic effects of smoked marijuana and dronabinol under well-controlled conditions using a validated experimental model of pain. Healthy male (N=15) and female (N=15) daily marijuana smokers participated in this outpatient study comparing the analgesic, subjective, and physiological effects of marijuana (0.00, 1.98, or 3.56% THC) to dronabinol (0, 10, or 20 mg). Pain response was assessed using the cold-pressor test (CPT): participants immersed their left hand in cold water (4 °C), and the time to report pain (pain sensitivity) and withdraw the hand from the water (pain tolerance) were recorded. Subjective pain and drug effect ratings were also measured as well as cardiovascular effects. Compared with placebo, marijuana and dronabinol decreased pain sensitivity (3.56%; 20 mg), increased pain tolerance (1.98%; 20 mg), and decreased subjective ratings of pain intensity (1.98, 3.56%; 20 mg). The magnitude of peak change in pain sensitivity and tolerance did not differ between marijuana and dronabinol, although dronabinol produced analgesia that was of a longer duration. Marijuana (1.98, 3.56%) and dronabinol (20 mg) also increased abuse-related subjective ratings relative to placebo; these ratings were greater with marijuana. These data indicate that under controlled conditions, marijuana and dronabinol decreased pain, with dronabinol producing longer-lasting decreases in pain sensitivity and lower ratings of abuse-related subjective effects than marijuana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.